Palisade Bio Closes $5M Underwritten Public Offering of Units and Warrants

PALISADE BIO, INC.

Issued 158,000 Class A Units (common + warrant) and 3,120,688 Class B Units (prefunded warrant + warrant) at $1.525/$1.5249 per unit.
Gross proceeds $5 million; net proceeds approximately $4.1 million after underwriting discounts and expenses.
Proceeds to fund Phase 1 trial of PALI-2108, pre-clinical studies, R&D, and working capital.
Repriced approximately 1,040,217 previously issued warrants to $1.40 per share for participating investor.
Underwriter Ladenburg Thalmann & Co. Inc.; 45-day overallotment option for up to 491,803 additional shares/warrants.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.